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Abstract (248 words) 
 
Vaccines in combination with chemotherapy have been shown to be safe in different tumor 
types. We investigated the immunological activity of the TroVax® vaccine in combination 
with pemetrexed-cisplatin chemotherapy in malignant pleural mesothelioma (MPM). 
In this first line, open-label, single-arm, phase 2 study, patients with locally advanced or 
metastatic MPM were enrolled. Eligible patients received up to 9 intramuscular injections of 
TroVax®, starting two weeks before chemotherapy and continuing at regular intervals 
during and after chemotherapy to 24 weeks. The primary endpoint was the induction of 
cellular or humoral anti-5T4 immune response (defined as a doubling of either response at 
any of six follow-up time points), with a target response rate of 64%.  
Of 27 patients, enrolled between Feb 2013-Dec 2014, 23 (85%) received at least three doses 
of TroVax® and one cycle of chemotherapy and were included in the per-protocol analysis 
(PPA). 22/23 patients (95.6%) developed humoral or cellular immune response to 5T4. Thus, 
the study reached its primary endpoint. Disease control was observed in 87% of patients 
(partial response: 17.4%, stable disease: 69.6%). The median progression-free survival was 
6.8 months and median overall survival 10.9 months. Treatment-related adverse events 
were comparable to those observed in patients with chemotherapy alone. Translational 
immunology studies revealed a circulating baseline immune signature that was significantly 
associated with long-term (>20 months in n=8/23, 34.8%) survival. 
In this phase 2 trial, TroVax® with pemetrexed-cisplatin chemotherapy showed robust 
immune activity, acceptable safety and tolerability to warrant further investigation in a 
phase 3 setting. 
 
 3 
Introduction  
Malignant pleural mesothelioma (MPM) is an incurable and fatal malignancy of the pleural 
membranes. MPM has a poor prognosis and patients have a median survival of 9-18 months 
in clinical trials.
1, 2
 To date, only two randomized phase III trials in MPM have shown benefit 
for one systemic treatment approach over another. In the first of these trials,
1
 448 patients 
were randomized to chemotherapy using pemetrexed plus cisplatin or cisplatin alone. 
Median overall survival (OS) was significantly longer in the pemetrexed-cisplatin arm (12.1 
vs. 9.3 months, p <0.02). As a result of this trial, pemetrexed-cisplatin was established as the 
chemotherapy standard of care for patients with MPM. For this reason, we chose 
pemetrexed-cisplatin as the chemotherapy regimen for this trial. Subsequently, the addition 
of bevacizumab to pemetrexed-cisplatin has been shown to further increase median survival 
by two to three months compared to chemotherapy alone.
2
 Despite the benefits seen from 
chemotherapy with or without the addition of bevacizumab, it is clear that new therapeutic 
strategies are urgently needed for MPM.   
There is significant recent interest in the potential role of immunotherapy in the 
management of patients with MPM, which has been shown to respond to various 
immunotherapeutic strategies in animal models and early phase clinical trials.
3
 Spontaneous 
regression, associated with improved immune parameters has also been reported.
4
 Indeed, 
prognostic significance of intratumoral immune cell subsets in MPM have revealed CD8+ T 
cells and CD20+ B cells as positive prognostic indicators 
5, 6
, whilst CD163+ macrophages and 
regulatory T cells (Treg) are negative indicators.
6,7
 Conversely, very few studies have 
addressed the significance of peripheral immune parameters to clinical outcome, though 
proliferating CD8+ T cells, co-expressing Ki67
8
 and dysfunctional dendritic cells
9
 have been 
described. Furthermore, blood parameters such as high white blood cell count, neutrophil 
 4 
to lymphocyte ratio (NLR), monocyte numbers and high monocyte to lymphocyte ratios 
have also shown negative prognostic value.
10-12
 This indicates that patient screening and 
stratification may improve clinical benefit, particularly in immunotherapy trials.       
 
Current studies are testing a range of immunotherapeutic approaches, such as treatment 
with a mesothelin-targeting chimeric antibody (amatuximab), type-I interferon delivered by 
an adenoviral vector, intrapleural viruses and antigen-specific vaccines, such as the Wilms 
tumor antigen-1 (WT-1) vaccine.
13
 The WT-1 vaccine has shown evidence of activity in a trial 
of 40 patients with MPM randomized to WT-1 vaccine or observation after multimodality 
treatment.  Immune checkpoint inhibitors have also been tested in MPM with mixed early 
results and their further clinical trials - single or combination treatments – are currently 
ongoing.
14, 15
 
 
5T4 is a 72 kDa oncofoetal glycoprotein that is expressed in many solid tumors but shows 
minimal or no expression in normal tissues.
16
 We have shown that 5T4 is widely expressed 
in mesothelioma tissue and on mesothelioma cell lines.
17
 Unlike WT-1 and mesothelin, 
which display subtype-restricted expression, often excluding the more aggressive 
sarcomatoid variant, 5T4 expression has been shown in all MPM subtypes.
17
 5T4-specific T 
cell responses were demonstrated by patieŶts’ peripheral ďlood ŵoŶoŶuĐlear Đells ;PBMCͿ 
and pleural fluid cells (Al-Taei at al., unpublished), making it a valid antigen for targeted 
therapies, including immunotherapy, in MPM. 
 
TroVax® (Oxford BioMedica, Oxford, UK) is a therapeutic cancer vaccine which consists of a 
highly attenuated vaccinia virus (modified vaccinia Ankara) containing the 5T4 glycoprotein 
 5 
gene. TroVax® has been administered to more than 500 patients with renal, colorectal and 
prostate cancer.
18
 These clinical studies showed that TroVax® is well-tolerated and induced 
5T4-specific antibody and/or cellular immune responses in the majority of patients. In 
addition, TroVax® was also well tolerated when used in combination with chemotherapy in 
patients with colorectal cancer.
19
  
 
Pemetrexed-cisplatin chemotherapy is seen as a UK and international standard of care for 
patients with MPM. We aimed to combine the TroVax® vaccine with first line pemetrexed-
cisplatin chemotherapy in MPM patients in a single-arm, single-center, phase II trial 
(SKOPOS), in order to determine 5T4-specific antibody and/or cellular immune responses, 
activity, safety and feasibility. Furthermore, we carried out retrospective 
immunohistochemistry, full blood count (FBC) and immunophenotypic analyses to identify 
potential immune prognostic indicators.
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Results  
 
Patient and treatment details 
Between Feb 2013, and Dec 2014, 29 patients were enrolled at Velindre Cancer Centre in 
Cardiff, UK. 23/29 patients (79%) received at least three doses of TroVax® and one cycle of 
chemotherapy and were included in the PPA (Figure 1). Six participants were not included in 
the PPA as four did not receive the minimum 3 injections, one patient was later found not to 
have mesothelioma, and one was found to have a co-primary cancer. Median age of the PPA 
participants was 66 years (IQR 61-70), 20/23 (87%) were male, 20/23 (87%) had epithelioid, 
3/23 (13%) had sarcomatoid MPM, and 12/23 (52%) had WHO PS of 0 (Table 1).  
The median number of TroVax® injections administered to PPA patients was nine (IQR 7-9): 
16/23 (70%) patients received all nine injections, 6/23 (26%) patients received between four 
and nine injections, and 1/23 (4%) patients received three injections. The reasons that seven 
patients missed injections are follows: two patients died, two withdrew due to adverse 
effects (AE), one withdrew due to disease progression, one withdrew to undergo surgery for 
MPM, and one patient missed the week 11 injection. Four cycles of pemetrexed-cisplatin 
chemotherapy treatment were successfully administered to 19/23 (83%) patients. Four 
patients did not complete four cycles of chemotherapy: two died and two withdrew due to 
AE. The median number of chemotherapy cycles was four (IQR 4-4). Median cisplatin DI was 
90% (IQR 75-100). Median pemetrexed DI was 95% (IQR 75-100). 
 
Primary endpoint – immune responses 
Table 2A summarizes the primary endpoint, the generation of cellular and/or humoral 
immune responses specific for the tumor antigen (5T4) delivered by the vaccine. As 22/23 
 7 
(96%) patients had an anti-5T4 response (either humoral or cellular), the study reached its 
primary endpoint. 17/23 (74%) of patients mounted humoral and 20/23 (87%) of patients 
developed cellular anti-5T4 immune responses, which were defined as doubling of immune 
responses from baseline. The longitudinal analysis of immune responses is shown on Table 
2B and a time-related summary on Figure 2. The frequency of responders to 5T4 peaked at 
week 10, followed by a gradual decrease. This may have been due to the accumulated 
effects of 4 cycles of chemotherapy that started at 4-weeks and ended at 13-weeks. All 
three patients with sarcomatoid MPM mounted 5T4-specific T cell responses while antibody 
doubling was observed in 2/3 patients.   In an independent preliminary study, involving 27 
lung cancer and MPM patients who received pemetrexed-cisplatin chemotherapy without 
the vaccine, 5T4-specific antibody levels were measured before and after chemotherapy. 
Only one patient had a doubling of the 5T4-antibody level (data not shown), indicating that 
if changes in 5T4 antibody levels are observed in the trial, they will be due predominantly to 
the development of specific immune responses to the vaccine.   
 
Clinical responses 
For the 23 patients evaluable for clinical response by 26 weeks, 0/23 (0%) patients achieved 
a complete response, 4/23 (17%) a partial response, 16/23 (70%) a stable disease and 3/23 
(13%) have progressed, giving an overall ORR of 17% (95% CI 5-39%) and disease control of 
87% (95% CI 66-97%; Table 3). The median PFS was 6.8 months (95% CI 3.6-8.9) (Figure 3A). 
Median OS was 10.9 months (95% CI 8.1-23.5) (Figure 3B). The median OS for sarcomatoid 
patients was 6.6 months. The median length of follow-up for seven patients still alive was 24 
months. 
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Adverse effects  
Treatment-emergent adverse events experienced are shown in supplementary material 
Table S2. All 23 patients (100 %) had at least one grade 1-2 treatment-emergent AE. Grade 
3-4 toxicities were seen in 11/23 (48%) patients: Grade 4 events included one patient with 
neutropenia and one with pleural effusion. Grade 3 events included three participants each 
with respiratory tract infection and thromboembolic events, and two participants with 
hypertension. There were also isolated grade 3 events: pyrexia, fall, cellulitis, phlebitis, and 
dyspnoea. There were no grade 5 toxicities. Grade 1-2 AE affecting more than 5 patients are 
summarized in Table S2.  
 
Analysis of circulating immune cells  
In this trial, 15 patients died within 14 months (Figure 3B) while the remaining 8 were still 
alive at 20 months. The frequency of patients alive in our cohort at 20 months (34.7%) 
correlates or is somewhat higher than the published frequency (24.8%) 
1
 and can be seen as 
the tail of the Kaplan Meyer curve (Fig 3B). We carried out a comparative analysis of FBC 
data and circulating immune cell phenotypes in patients with >20 months survival 
(8/23=34.7%) vs. those with <20 months (15/23=65.3%) survival. While there was no 
evidence that PFS was associated with baseline blood parameters (Table 4A) or that the 
>20m patients had any significantly different baseline FBC parameters, we found that NLR 
and MLR were significantly lower at week 4, when patients have only received 2 doses of 
vaccine but no chemotherapy, in the >20m group (Table 4B). Comparative analysis also 
indicated that more patients mounted T cell responses to 5T4 in the >20m group (Fig 4A) 
and T cell responses were generated with a broader 5T4 epitope specificity in the >20m 
compared to the <20m group (Fig 4B).  
 9 
We also assessed the comparative frequencies of T cell, Treg cell, monocyte and MDSC 
subsets in baseline samples. As shown in Table 5, the immune parameters, found to be 
significantly different between the two groups were: higher CD8:CD4 ratios and lower naïve 
CD4 T cell frequencies in the >20m patients. There were no differences between the 
frequencies of either total or activated Treg cells between the groups, and the frequencies 
of main myeloid cell subsets were also comparable. These results indicate that elevated 
peripheral CD8+/CD4+ T cell ratio in MPM patients is a positive prognostic indicator in 
TroVax® treatment.   
 
Tissue immunohistochemistry 
19/23 pre-treatment FFPE samples were available for the immunohistochemical analysis of 
5T4 expression and CD8+ T cell infiltration. 5T4 expression has been observed in all samples, 
although at varying degrees. In some cases, distinct expression was only observed on the 
tumor surface, while in others expression was observed in the tissue or in both sites (Fig 
5A,B). There was no difference in the frequency of 5T4+ tumor cells in the tissue of long-
term and short-term survivors, respectively (32.7±30.3% vs. 46.5±36.2%), however, 
expression was markedly lower in the sarcomatoid tumors (2.33±2.3%). CD8+ T cell 
infiltration was also studied. CD8+ cells were either scattered in the tissue or accumulated 
at the interface of malignant and normal tissues; in some cases both patterns were present 
(Fig 5A,C). Although there was a trend for higher CD8+ T cell infiltrate in the tissue of long-
term vs. short-term survivors (28.4±33.3% vs. 23.1±24.8%), the difference was not 
significant. In contrast, CD8+ T cell infiltration was markedly lower in sarcomatoid tissues 
(11.83±15.8%).  While the number of patients is insufficient for meaningful statistical 
analysis, we observed both 5T4 expression and CD8+ T cell infiltration at >10% of the tissue 
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in 50% of long-term survivors, while this was only true in 25% of short-term survivors and in 
none of the sarcomatoid tumors.   
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Discussion   
In patients with previously untreated MPM, the SKOPOS trial reached its primary endpoint, 
showing that TroVax® in combination with pemetrexed-cisplatin chemotherapy results in 
95.7% of patients developing immune responses against the 5T4 tumor antigen. In the 
independent preliminary study, pemetrexed-cisplatin chemotherapy alone did not result in 
immune responses to the 5T4 tumor antigen in 26/27 (96.3%) patients, so the immune 
responses seen in the trial are overwhelmingly likely to have been generated by the TroVax® 
vaccine. 
 
The high rate of immune responses generated by the vaccine, despite being given in 
combination with potentially immunosuppressive chemotherapy, shows that MPM patients 
are capable of generating or reactivating tumor antigen specific T or B cell responses in first 
line treatment settings. The combination of TroVax® plus chemotherapy was well tolerated, 
with no significant additional toxicity seen as a result of the TroVax® vaccine. The proportion 
of patients getting one or more grade 3 or 4 toxicities was 48%, which compares to 62% 
reported in the chemotherapy-only arm of the MAPS trial. 
2 
 
 
With respect to clinical outcomes in SKOPOS, the median PFS of 6.8 months and median OS 
of 10.9 months are comparable to the median time to progression of 5.7 months and 
median OS of 12.6 months reported in the Pemetrexed-cisplatin arm of the Vogelzang trial, 
demonstrating that the combination with TroVax® has similar clinical activity. 
1
 Importantly, 
we observed higher disease control (87% vs. 41.3%) than that reported in the Vogelzang 
trial and a greater proportion of patients achieved >20 months OS than those in the 
Vogelzang trial (34.7% vs. 24.8%). A feature of some contemporary immunotherapy trials in 
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solid tumors is the observation that the Kaplan-Meier survival curves do not start to 
separate from the standard chemotherapy arm in the initial months, and clinically 
meaningful differences only emerge when survival beyond the median timepoint is 
examined. For example, in the Checkmate 017 trial of the PD-L1 inhibitor nivolumab versus 
docetaxel chemotherapy in the advanced squamous cell lung cancer second line setting, 
median PFS was less than one month longer in the nivolumab-treated patients. However, 
this relatively modest increase in median PFS translated into a more impressive difference in 
one year PFS: 21% seen with nivolumab compared to 6% with chemotherapy.
24
 Similar 
results were seen for OS in the sister Checkmate 057 trial in the second line advanced non-
squamous lung cancer setting.
25
 In a small, non-randomized trial such as SKOPOS it is not 
possible to draw any definitive conclusions about the significance of 34.7% long-term 
survivors, but one explanation is that an immune-mediated effect - as seen in the lung 
cancer Checkmate trials of nivolumab – may be driving a minority of patients to longer 
disease control and hence survival.  
 
It is clear that not all tumors respond to immunotherapy. However, a strong correlation 
between tumor-infiltrating CD8+ T cells and favorable disease prognosis serves as a 
powerful indirect evidence for immune involvement in MPM.
26
 Although our study was not 
statistically powered to analyze correlation between T cell infiltration and clinical benefit, 
we observed a trend for more CD8 infiltration in patients with longer survival. Despite these 
observations, to date, trials testing a variety of immunotherapeutic approaches in MPM 
have reported only modest clinical outcomes. For example, the anti CTLA-4 inhibitor 
Tremelimumab showed no improvement in overall survival compared to placebo as a later-
line therapy in patients with pleural and peritoneal malignant mesothelioma.
27
  In the single 
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arm Keynote 028 trial, the anti PD-L1 antibody Pembrolizumab reported more encouraging 
results, with a median PFS of 5.8 months and a disease control rate of 76% in MPM patients 
previously treated with chemotherapy.
28
  
 
The biggest limitation of the SKOPOS trial is the single arm design with no control group; no 
definitive conclusions can be drawn when comparing the clinical outcomes from SKOPOS 
with published historical controls of patients treated with chemotherapy alone. However, 
we did show that pemetrexed-cisplatin chemotherapy alone elicited a 5T4 immune 
response (doubling of antibody response) in only 1/29 (3.4%) lung cancer and mesothelioma 
patients so we are confident that the immunological activity seen in the SKOPOS trial is 
predominantly due to the TroVax® vaccine. Another observation we made, albeit only in 
3/23 of samples, that patients with sarcomatoid MPM were just as able to mount systemic 
5T4 immune responses following the vaccine treatment as the cohort with epithelioid 
tumors. However, the pre-treatment tissue samples revealed low antigen expression and 
weak T cell infiltration into the tissue, indicating more powerful immunosuppression or at 
least lack of immune support in the tumor microenvironment of these patients, potentially 
contributing to the more rapid disease progression.   
 
Predictive biomarkers are important in providing bespoke cancer treatment for patients. 
The results from SKOPOS suggest that inducing immune responses against the 5T4 tumor 
antigen alone does not select patients more likely to have a longer survival - almost all 
patients in the study developed such an immune response. We have carried out 
retrospective data-analysis to look for possible differences between those surviving >20m 
vs. <20m. We observed a high CD8:CD4 T cell ratio in long-term survivors, consistent with 
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the positive prognostic significance of CD8+ T cells in MPM patients.
26
  We also identified 
elevated levels of CD4+ naïve T cell in the short-term survivor group of patients. This may 
indicate that MHC Class II antigen presentation was suboptimal in these patients. Although 
naïve T cells exposed to high levels of TGF in the plasma are easily hijacked to become 
Tregs 
29
, we did not observe significant differences in Treg frequencies in the circulation of 
these patients. However, we have not studied the intratumoral frequencies of Treg that 
have a known prognostic significance.
7
 
Again, no differences were observed in classical monocyte frequencies (CD14+ HLA-DR+), or 
in the frequencies of cells expressing M-MDSC, G-MDSC or E-MDSC markers.
30
  
  
Given the disappointing results of numerous cancer vaccine trials, it seems unlikely that a 
vaccine alone will have a significant impact on solid tumors, although this type of treatment 
may be beneficial for some patients. While the combination of a vaccine and chemotherapy 
may not be optimal, as chemotherapy may damage expanding T cell populations, the 
combination of a vaccine and a checkpoint inhibitor may lead to synergistic results. 
Checkpoint inhibitors may also overcome potentially inhibitory signalling pathways that 
switch off T-cells and dampen the immune response to the tumor antigen. We believe the 
SKOPOS trial participants are representative of a significant proportion of newly diagnosed 
MPM patients in the UK, and the results of any subsequent clinical trials using combination 
treatment schedules would be broadly applicable. 
  
 15 
Materials and methods 
Study design and participants  
We undertook an open-label, single-arm phase II trial (SKOPOS) at Velindre Cancer Centre, 
Cardiff, UK. Patients with locally advanced or metastatic, histologically or cytologically 
confirmed, MPM were potentially eligible for the trial. Inclusion criteria iŶĐluded age ≥ϭ8 
years, World Health Organization (WHO) performance status (PS) 0-1 and an estimated life 
eǆpeĐtaŶĐǇ of at least siǆ ŵoŶths. HeŵatologiĐal iŶĐlusioŶ Đriteria ǁere heŵogloďiŶ ≥10 
g/dL, total ǁhite Đell ĐouŶt ≥3 ǆ ϭϬ9/L, neutrophil count >1.5 x 109/L, lǇŵphoĐǇte ĐouŶt ≥Ϭ.8 
x 10
9
/L, monocyte count <1 x 10
9
/L and platelet count 100-500 x 10
9
/L. Patients also had to 
have adequate renal and liver function.  
Exclusion criteria included major surgery, serious infection or radiotherapy (superficial 
radiotherapy to chest wall sites was permitted) in the four weeks prior to trial entry, 
previous TroVax® or chemotherapy treatment, cerebral metastases or history of allergic 
response to previous vaccinia vaccinations.  
All patients provided written informed consent before enrolment. Approval from a UK 
Research Ethics Committee, (Ref: GTAC174), and Medicines and Health Care Products 
regulatory Committee (EudraCT2010-023230-22) was obtained. The trial was coordinated 
by the Wales Cancer Trials Unit at Cardiff University and sponsored by Velindre NHS Trust. 
The trial was conducted in accordance with the principles of the Declaration of Helsinki and 
the ICH Good Clinical Practice, and registered with ClinicalTrials.gov (NCT01569919). 
In order to establish that chemotherapy alone does not elicit an immune response, an 
independent pre-study was also conducted, in which blood samples from 27 lung cancer 
and MPM patients were tested for antibody responses to the 5T4 antigen before and after 
pemetrexed-cisplatin chemotherapy. 
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Procedures 
As summarized on the CONSORT flow diagram (Figure 1), eligible patients received TroVax® 
by intramuscular injection at a dose of 1 x 10
9
 TCID50/mL in 1mL, given on Day 1 or 2 of 
weeks 1, 3, and then every three weeks to week 24. Patients also received 4 cycles of 
Pemetrexed (500 mg/m
2
 over 10 min) and Cisplatin (75mg/m
2
 over 1 h), given on day 3 or 4, 
from week 4. Folic acid, vitamin B12 and corticosteroids were administered according to 
protocol. 
A baseline CT scan of the chest and upper abdomen had to be undertaken with 
documentation of known measurable or evaluable disease parameters using the modified 
Response Evaluation Criteria in Solid Tumors (RECIST) criteria for mesothelioma.
20
 WHO PS 
and toxicity were collected at baseline according to the Common Terminology Criteria for 
Adverse Events (v4.02). Tumor response was assessed with CT at week 16, 26, 39 and 52 
weeks and with RECIST V1.1. Toxicity assessments were carried out at week 4, 7, 10, 13, 16, 
26 and 34 with serious adverse events being collected in real time.  
 
Blood sample collection and processing 
Venous blood samples were collected into EDTA vacutainers (Greiner #455036) at six time 
points for immunological testing: baseline (80 mL), week 4, 7, 10, 13, 26 and 34 (50 mL 
each). PBMC were isolated by density gradient centrifugation on Histopaque (Sigma 
#H8889), within 30 min of collection. The plasma was frozen in 10 cryovials (Sarstedt 
#72.377) in 0.5 mL aliquots at -80
o
C. PBMC were frozen in freezing media comprising 10% 
DMSO (Sigma #D2650), 20% FBS (Gibco, #26140-079 lot #1233760; batch-tested for low T 
cell mitogenicity) in RPMI 1640 media (Sigma #BE12-167F), supplemented with 2 mM L-
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Glutamine (Lonza #BE17-605E), 100 U/ml penicillin/100 g/mL streptomycin (Lonza #BE17-
603E), 25 mM HEPES (Sigma #H0887) and sodium pyruvate (Sigma #S8636). PBMC were 
frozen as one 2.6x10
7
 vial, with the remaining cells in around 1.3x10
7
 cells per vials at  -80
o
C 
in a CoolCell container (VWR) overnight, before transferring to vapor phase of liquid 
nitrogen. T cell assays were carried out when all longitudinal samples were obtained.   
 
Measurement of 5T4-specific T cell responses 
The intracellular cytokine staining protocol used to assess 5T4 specific T cell responses was 
optimized prior to the trial
21
 (and unpublished work). 5T4 peptides (42 in total) spanning the 
entire 5T4 protein sequence (15-mers, overlapping by 5 amino acids) were synthesised by 
ProImmune at >85% purity. They were reconstituted in DMSO at a concentration of 10 
mg/mL and stored in -20
o
C. Peptides were pooled into 4 separate groups (peptide pools  1-
10, 11-20, 21-31 and 32-42) prior to use. Pools of viral peptides (Class I and II epitopes) 
representing cytomegalovirus, Epstein-Barr and influenza virus (CTL #CTL-CEF-001 and #CTL-
CEFT-001) epitopes were used as positive and DMSO as negative control. Frozen PBMC 
samples were thawed and viability determined with trypan blue (Sigma #T8154) staining. 
Any samples with less than 85% viability were not used. PBMC (8x10
5
-10
6
) were seeded in 
48-well plates (Greiner #677180) in 1 mL supplemented RPMI
 
containing 10% FBS. 5T4 
peptide pools (20 g/mL), viral peptide pool (5 g/mL) and DMSO (1 L/mL; negative 
control) were added to relevant wells in addition to 1000 U/mL IFN(R&D #11101-2), 20 
ng/mL IL-1 and 500 U/mL IL-6 (Peprotech #200-01B and 200-06, respectively). Cells were 
cultured for 6 days then restimulated using autologous B lymphoblastoid cell lines (BLCL) at 
20:1 ratio (5x10
4
 BLCL to 1x10
6
 PBMC). BLCL were loaded with 10 g/mL of each 5T4 
peptide pool, or 2.5 g/mL viral peptide pool or volume equivalent of DMSO, for 4 h at 37oC. 
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BLCL were co-incubated with the relevant PBMC in FACS tubes (VWR #352054) for 1 h at 
37
o
C prior to adding Golgi Plug (0.5 L; BD #555029) and Golgi Stop (0.35 L; BD #554724) in 
a final volume of 500 L followed by a further 12-13 h incubation. Cells were washed in PBS 
(Lonza #BE17-512F) and labelled with 0.5 L LIVE/DEAD e-Fluor 780 fixable dye (Affymetrix 
eBioscience #65-0865-14) in 500 L at 4oC for 30 min. Cells were fixed in 100 L Affymetrix 
eBioscience fixation buffer (#00-8222-49) for 15 min at room temperature. Cells were then 
washed once in PBS, permeabilized in 100 L 1x permeabilization buffer (Affymetrix 
eBioscience #00-8333-56) and labelled with 2.5 L each of CD3 PE-Cy7 (#25-0038), CD4 APC 
(#17-0049), CD8a PerCP-Cy5.5 (#45-0088), IFN PE (#12-7319), TNF e-fluor 450 (#48-7349) 
and IL-2 FITC (# 11-7029; all from Affymetrix eBiosciences) antibodies for 40 min at room 
temperature in the dark. Samples were then washed in staining buffer, resuspended in 230 
L staining buffer and run on a BD FACSVerse flow cytometer which was normalized daily 
with CS&T bead tracking. Compensation controls were established with cells labelled with 
one antibody at a time. Data were acquired with BD FACSuite software. Gating for cytokine-
produĐiŶg T Đells ǁas Đarried out ďǇ folloǁiŶg the CaŶĐer IŵŵuŶotherapǇ CoŶsortiuŵ’s 
guidelines.
22
 This was based on an international assay/gating harmonization exercise in 
which our laboratory took part (Supplementary Figure 1). All results were audited and raw 
data can be provided on request.  
 
 
Measurement of Antibody Responses 
5T4- and MVA-specific antibody responses were determined from longitudinal plasma 
samples using a validated semi-quantitative Enzyme linked immunosorbant assay (ELISA). 
23
 
 
Immune cell phenotyping 
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PBMC (2x10
5
/tube) were labelled in 100 L staining buffer for T cells, monocytes, myeloid-
derived suppressor cells (MDSC) and Treg cells using antibodies detailed in Table S1. Cells 
were labelled for surface markers for 40 min on ice. Cells in the Treg panel were then fixed, 
permeabilized and further labelled with Foxp3 FITC and Ki67 APC, according to the 
ŵaŶufaĐturer’s iŶstruĐtioŶs. All Đells ǁere ruŶ oŶ a BD FACSVerse floǁ ĐǇtoŵeter aŶd 
analysed with Diva 8 software.   
 
Immunohistochemistry 
Formalin fixed paraffin embedded (FFPE) sections were prepared. Antigen retrieval was 
performed on the Dako Omnis platform by heating slides in retrieval solution at 97◦ C for 30 
min then at room temperature and washing in distilled water. Sections for 5T4 (R&D 
Systems # MAB 4975) underwent high pH 8.5 EDTA antigen retrieval. Sections for CD8 (Dako 
Agilent mouse monoclonal clone C8/144B) had pH 6.0 citrate antigen retrieval. 5T4 antibody 
was used at 1:75 dilution of the stock of 0.5 mg/ml. CD8 antibody was in a ready to use 
formulation. Both 5T4 and CD8 had primary antibody incubations at 37
o
C (5T4 for 30 min, 
CD8 for 20 min) with detection by the DAB Omnis kit. Slides were analyzed on a Nikon 
eclipse E600 light microscope by an experienced mesothelioma pathologist (RLA). A semi-
quantitative evaluation of 5T4 staining was made noting either no, mild, moderate, intense 
membranous expression of surface and deep tumor tissue. A semi-quantitative evaluation 
of cytotoxic CD8 T-cells was made noting a nil, mild, moderate or plentiful response within 
tumor or at the tumor-stromal interface. Percentages and patterns of expression were 
recorded. 
  
Outcomes 
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The primary outcome measure was pre-defined as a doubling of anti-5T4 immune responses 
compared to those at baseline at any of the six time points. Secondary outcome measures 
included the safety and tolerability of TroVax® in combination with pemetrexed/cisplatin, 
progression-free survival (PFS), objective response rate (ORR), and OS. The study also 
investigated the relationship between immune and clinical responses, the utility of baseline 
platelet count, monocyte count, hemoglobin levels, neutrophil:lymphocyte ratios (NLR) and 
monocyte:lymphocyte ratios (MLR) as predictors of treatment benefit. The latter two were 
also analyzed at the 4-week time point. 
 
Statistical analysis 
We used a FleŵiŶg’s single arm design with the outcome measure of immune response to 
the 5T4 antigen. If less than 40% of patients demonstrated an increased response from 
baseline, then we would not pursue further research. If an increased response was seen in 
64% or more of patients then this would justify further research in the vaccine in patients 
with MPM. Setting =0.05 (1-sided) and 80% power, 26 participants were required. If a 
doubling of 5T4 was seen in at least 16 patients, the null hypothesis that the vaccine does 
not elicit an immune response could be rejected. A per protocol analysis (PPA) was used 
where a patient had to receive at least the first three TroVax injections and the first cycle of 
chemotherapy (at full or reduced dose). PFS was calculated from the day of trial entry to the 
date of first clinical evidence of local progression or death (of any cause). Patients 
progression-free and alive were censored at the time last seen. Extended survival time was 
collected from the site beyond the end of the one-year follow-up after obtaining ethical 
approval. OS was calculated from the date of trial entry to the day of death (any cause). 
Those still alive were censored at the time last seen. PFS and OS were presented in time to 
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event format using Kaplan-Meier curves with median time and their corresponding 95% CIs. 
In a planned exploratory analysis a Cox proportional hazard model was used to explore 
whether baseline platelet count, baseline monocyte count and baseline hemoglobin predict 
time to progression. The univariate hazard ratios for each predictor are presented with their 
corresponding p-value. A logistic regression model was used to explore the effect of 
hemoglobin, hematocrit, soluble mesothelin and baseline 5T4 antibody level on the post-
treatment 5T4 antibody response. The primary endpoint and other secondary categorical 
endpoints (best response by 26 weeks) were presented as % and 95% CIs. Percentage dose 
intensity (DI) was calculated as total dose received in mg per m
2
 (m
2
)/total expected dose 
x100. All analysis used STATA 14.0.  
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Figure legends 
Figure 1. CONSORT Flow diagram of patients allocated for the SKOPOS trial. 
 
Figure 2. Summary of any 5T4-specific immune response in a longitudinal study. The bars 
represent the proportions (%) of patients whose immune response was ≥2-fold to any 5T4 
peptide group compared to their immune responses at baseline.  The six time points are 
indicated on the X-axis.  
 
Figure 3. Kaplan-Meier curves for (A) Progression-free survival (PFS), (B) Overall survival 
(OS).  
 
Figure 4. T cell responses to 5T4 peptides by long term vs. short term survivors. (A) The 
proportions of patients who generated CD4+ or CD8+ or both types of T cell responses to 
the 5T4 antigen. (B) The average frequencies of peptide groups that T cell responses were 
generated against at different time points during the trial. (A,B) <20 mo (black) represents 
patients with less than 20 months, while >20 mo (gray) those with more than 20 months OS. 
 
Figure 5. Immunohistochemistry of 5T4 expression and CD8+ T cell infiltration in pre-
treatment tissue. (A) Expression levels of 5T4 (i) and CD8 (ii) in the specimens of long term 
survivors (>20 mo; ), short-term survivors (<20 mo; ) or sarcomatoid patients (sarc; ). 
Each symbols represents a different patient. The vertical bars represent mean of expression. 
(iii) The combination of results from (i) and (ii). Reference lines represent 10% of expression. 
(B) Representative examples of 5T4 expression in epithelioid tissue. (i) High tissue 
expression, (ii) high tumor tissue and surface expression, (iii) low tissue expression. (C) 
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representative examples of CD8+ T cell infiltration. (i) high frequency scattered tissue 
infiltration, (ii) accumulation at the tumour margin, (iii) low level of tissue expression. 
Magnifications are 200x, except for Cii (100x). 
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Tables  
Table 1: Participant baseline characteristics 
Characteristics Results (N=23) 
Age
1
 66 (61-70) 
Sex   
  Male 20 (87.0%) 
  Female 3 (13.0%) 
WHO performance status   
  0 12 (52.2%) 
  1 11 (47.8%) 
Mesothelioma type   
  Epithelioid 20 (87.0%) 
  Sarcomatoid 3 (13.0%) 
    
Mesothelioma stage   
  Stage II 8 (34.8%) 
  Stage III 13 (56.5%) 
  Stage IV 2 (8.7%) 
Platelets
1
 351 (250-407) 
Monocytes
1
 0.6 (0.4-0.8) 
Hemoglobin
1
 13.8 (12.7-14.7) 
1 – Median (IQR) 
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Table 2: Immune responses 
A. Summary of overall immune responses – primary endpoint 
Measurements Results (N=23) 
Humoral 5T4 overall response 17 (73.9%)* 
Cellular 5T4 overall response 20 (87.0%)  
Any overall response (humoral or 
cellular 5T4 immune response) 22 (95.7%)  
*Number of patients responded (%) 
 
 
B. Detailed immune responses – time kinetics 
  
Immune 
parameters 
n/N (%) patients 
Week 4 Week 7 Week 10 Week 13 Week 26 Week 34 
CD4 IFN 4/21 
(19.05%) 
12/22 
(54.55%) 
11/22 
(50.00%) 
7/18 
(38.89%) 
4/15 
(26.67%) 
4/11 
(36.36%) 
CD8 IFN 1/21 
(4.76%) 
5/22 
(22.73%) 
5/22 
(22.73%) 
5/18 
(27.78%) 
4/15 
(26.67%) 
2/11 
(18.18%) 
CD4 TNF 2/21 
(9.52%) 
3/22 
(13.64%) 
5/22 
(22.73%) 
1/18 
(5.56%) 
4/15 
(26.67%) 
3/11 
(27.27%) 
CD8 TNF 0/21 
(0%) 
0/21 
(0%) 
2/22 
(9.09%) 
2/18 
(11.11%) 
2/15 
(13.33%) 
1/11 
(9.09%) 
CD4 IL-2 3/21 
(14.29%) 
3/22 
(13.64%) 
5/22 
(22.73%) 
3/18 
(16.67%) 
6/15 
(40.00%) 
2/11 
(18.18%) 
CD8 IL-2 3/21 
(14.29%) 
2/22 
(9.09%) 
3/22 
(13.64%) 
3/18 
(16.67%) 
1/15 
(6.67%) 
1/11 
(9.09%) 
Humoral 5T4 3/23 
(13.04%) 
12/23 
(52.17%) 
10/22 
(45.45%) 
9/19 
(47.37%) 
10/16 
(62.50%) 
5/12 
(41.67%) 
Cellular 5T4 9/21 
(42.86%) 
13/22 
(59.09%) 
14/22 
(63.64%) 
11/18 
(61.11%) 
9/15 
(60.00%) 
5/11 
(45.45%) 
Any (cellular or 
humoral 5T4) 
11/23 
(47.83%) 
19/23 
(82.61%) 
20/22 
(90.91%) 
15/19 
(78.95%) 
13/16 
(81.25%) 
9/12 
(75.00%) 
Humoral MVA 22/23 
(95.65%) 
23/23 
(100.00%) 
22/22 
(100.00%) 
18/19 
(94.74%) 
16/16 
(100.00%) 
12/12 
(100.00%) 
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Table 3. Clinical responses 
 
Best response (pleural disease, target or non-target tumor)
1
 
  Complete response 0/23 (0%) 
  Partial response 4/23 (17.4%) 
  Stable disease 16/23 (69.6%) 
  Progressive disease 2/23 (8.7%) 
  Unknown
2
 1/23 (4.3%) 
ORR (CR+PR)
1
 4 /23 (17.4%)  
Disease Control Rate (CR+PR+SD)
1
 20/23 (87.0%)  
Median PFS, months
3
 6.8 (3.6-8.9) 
Rate of PFS at 6 months
4
 60.6% (37.8-77.2%) 
Rate of PFS at 12 months
4
 23.3% (8.5-42.2%) 
Median OS, months
3
 10.9 (8.1-23.5) 
Rate OS at 6 months
4
 82.6% (60.1-93.1%) 
Rate OS at 12 months
4
 43.5% (23.3-62.1%) 
Follow-up, months (alive)
3
 24.0 (19.3-NR) 
1 – Number of patients n/23 (% responders)  
2 – RECIST data is not available for one patient 
3 – months (95% CI) 
4 – % of patients (95% CI)  
NR –Not reached 
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Table 4A. Analysis of full blood count data 
 
Variable Hazard Ratio Lower bound of 
95% confidence 
interval 
Upper bound of 
95% confidence 
interval 
p-value 
Platelets 0.998 0.993 1.003 0.43 
Monocytes 0.693 0.073 6.536 0.75 
Haemoglobin 1.217 0.897 1.651 0.21 
Haematocrit*10 1.903 0.628 5.767 0.26 
Mesothelin 0.937 0.857 1.025 0.16 
Humoral 5T4 1.007 0.975 1.040 0.67 
Exploratory univariate analysis of baseline blood parameters and PFS 
 
Table 4B.  Retrospective analysis of FBC 
 
 
 
 
 
 
 
 
 
 
 
(a) Patients who survived >20 weeks 
(b) Patients who died before 20 weeks 
(c) P value by one sided t-test 
(d) Neutrophil:lymphocyte ratio 
(e) Monocyte:lymphocyte ratio 
B: baseline; W4: 4 weeks after entering trial  
 
  
 >20 weeks
a
  <20 weeks
b
  p-value
c
 
Monocytes (B) 0.587±0.176 0.707±0.19 0.0833 
Platelets (B) 343.8±126 343.5±113 0.389 
Haematocrit (B) 0.406±0.047 0.413±0.003 0.348 
NLR
d
 (B) 3.05±1.61 3.268±1.55 0.378 
NLR (W4) 2.401±1.25 3.321±0.98 0.041(*) 
MLR
e
 (B) 0.324±0.099 0.415±0.173 0.0747 
MLR (W4) 0.268±0.111 0.415±0.171 0.021(*) 
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Table 5. Phenotypic analysis of circulating immune cells at baseline 
 
T cells <20 months >20 months p-value 
CD8:CD4 Ratio  0.571±0.079 0.995±0.389 0.035 (*) 
CD4+CD27+CD45RA- (CM) 34.07±3.374 38.59±6.430 0.249 
CD4+CD27+CD45RA+ (N) 59.38±3.957 42.93±7.629 0.023 (*) 
CD4+CD27-CD45RA- (EM)  4.258±0.653 6.758±2.375 0.104 
CD4+CD27-CD45RA+ (TEM) 2.292±0.948 11.72±9.717 0.098 
CD8+CD27+CD45RA- (CM) 30.13±3.844 22.41±5.384 0.127 
CD8+CD27+CD45RA+ (N) 42.10±4.734 44.98±8.891 0.379 
CD8+CD27-CD45RA- (EM)  5.408±1.098 3.919±1.188 0.201 
CD8+CD27-CD45RA+ (TEM) 22.37±5.650 28.72±9.866 0.276 
Treg cells    
Treg (CD3+CD4+CD25+Foxp3+) 5.052±0.368 5.938±1.077 0.174 
CTLA-4+ of Treg 5.848±0.623 6.730±2.291 0.319 
Ki67+ of Treg 22.45±2.116 20.26±2.049 0.256 
Myeloid cells    
(DC) CD14- HLA-DR+  5.018±0.470 6.269±1.149 0.123 
(MPh) CD14+ HLA-DR+  8.682±1.044 7.263±1.070 0.198 
PDL-1+ MPh 11.10±2.085 12.30±3.137 0.721 
CD200R+ PDL-1+ MPh 8.613±1.780 6.422±1.898 0.222 
MDSC     
M-MDSC (CD14+ HLA-DR- CD11b+ CD15-) 4.468+3.079 3.317+1.584 0.186 
G-MDSC (CD14- CD33- CD15- CD11b+) 0.028+0.011 0.276+0.555 0.186 
E-MDSC (Lineage- CD15- CD11b+ CD33+) 0.079+0.098 0.502+1.01 0.058 
 
C: central memory; N: naïve; EM: effector memory; TEM; terminally differentiated effector 
memory. MPh; macrophage. 
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